Ellipticine

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action.

Ellipticine is a DNA intercalating agent and a DNA topoisomerase II inhibitor. Ellipticine is also a natural product, isolated in 1959 from the Australian evergreen tree of the Apocynaceae family. Ellipticine was found to be an extremely promising anticancer drug. The planar polycyclic structure was found to interact with DNA through intercalation, exhibiting a high DNA binding affinity (10(6) M(-1)). The presence of protonatable ring nitrogens distinguished ellipticine from other simple intercalators. Both monocationic and uncharged species were found to be present under physiological conditions. The positive charge stabilized the binding of ellipticine to nucleic acids, while the more lipophilic uncharged compound was shown to readily penetrate membrane barriers. The structural nature of these compounds offers a plausible basis for the implication of multiple modes of action, including DNA binding, interactions with membrane barriers, oxidative bioactivation and modification of enzyme function; most notably that of topoisomerase II and telomerase.

CCG-36483; CCG36483; CCG 36483; DB-052047

Angiogenesis

VEGFR

Topo II

Cancer

——

519-23-3

246.31

C17H14N2

98%

DMSO : 5.8 mg/mL. 23.55 mM;

c12c(c(c3c(c2C)ccnc3)C)c2c([nH]1)cccc2

5,11-dimethyl-6H-pyrido[4,3-b]carbazole

(-20℃)

With Ice Pack

≥ 2 years